Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

almorexant

PreclinicalSmall molecule

MMidnight Pharma, LLC

1

Indications

5

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orexin AntagonistCompleted

Orexin AntagonistPreclinical

Completed

Clinical

Trials by Indication[1]

Insomnia2 trials

Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Completed·MMidnight Pharma, LLC·Phase 3·NCT00608985·709 enrolled

Almorexant in Primary Insomnia

Completed·MMidnight Pharma, LLC·Phase 1·NCT00640848·161 enrolled

Orexin Antagonist1 trial

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

Completed·NNorthern California Institute of Research and Education·N/A·NCT01243060·203 enrolled

Tics1 trial

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT01954589·56 enrolled

Abuse Potential1 trial

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

Completed·MMidnight Pharma, LLC·Phase 1·NCT01987739·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for almorexant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — almorexant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for almorexant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Midnight Pharma, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMidnight Pharma, LLC

Related News